Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses ARDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ARDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Raab | $797,000 | $0 | $2,953,724 | $3,413,948 | $627,638 | $0 | $3,861 | $7,796,171 |
| President, Chief Executive Officer and Director | ||||||||
| Edward Conner | 213,019 | 0 | 1,574,775 | 1,836,116 | 0 | 0 | 0 | 3,623,910 |
| Former Chief Medical Officer | ||||||||
| Justin Renz | 464,434 | 0 | 1,578,559 | 1,182,722 | 250,425 | 0 | 75,543 | 3,551,684 |
| Former Chief Financial and Operations Officer | ||||||||
| Susan Hohenleitner | 120,929 | 330,000 | 735,949 | 2,194,078 | 56,416 | 0 | 0 | 3,437,372 |
| Chief Financial Officer | ||||||||
| John Bishop | 240,000 | 0 | 1,004,980 | 1,148,032 | 116,510 | 0 | 3,000 | 2,512,522 |
| Chief Technical and Quality Officer | ||||||||
| Elizabeth Grammer | 527,126 | 0 | 708,002 | 818,313 | 246,695 | 0 | 3,481 | 2,303,617 |
| Former Chief Legal and Administrative Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Raab | $7,796,171 | — | — | — |
| Edward Conner | 3,623,910 | — | — | — |
| Justin Renz | 3,551,684 | — | — | — |
| Susan Hohenleitner | 3,437,372 | — | — | — |
| John Bishop | 2,512,522 | — | — | — |
| Elizabeth Grammer | 2,303,617 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Raab | Director | 2026-05-15 | D | 41,666 | $6 | $261,612 | Common, open-market sale | Form 4 ↗ |
| Michael Raab | Director | 2026-05-15 | A | 20,833 | 1 | 20,625 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-05-15 | D | 20,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph James Reilly | See Remarks | 2026-05-21 | D | 2,683 | 6 | 16,816 | Common | Form 4 ↗ |
| Joseph James Reilly | See Remarks | 2026-05-21 | D | 1,036 | 6 | 6,493 | Common | Form 4 ↗ |
| John Bishop | See Remarks | 2026-05-21 | D | 2,306 | 6 | 14,453 | Common | Form 4 ↗ |
| James Parker Brady | Chief Human Resources Officer | 2026-05-21 | D | 1,846 | 6 | 11,570 | Common | Form 4 ↗ |
| Eric Duane Foster | Chief Commercial Officer | 2026-05-21 | D | 3,166 | 6 | 19,843 | Common | Form 4 ↗ |
| Mike Kelliher | Chief Business Officer | 2026-05-21 | D | 1,870 | 6 | 11,720 | Common | Form 4 ↗ |
| Mike Kelliher | Chief Business Officer | 2026-05-21 | D | 2,478 | 6 | 15,531 | Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-05-21 | D | 1,503 | 6 | 9,420 | Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-05-21 | D | 1,911 | 6 | 11,977 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-05-21 | D | 14,933 | 6 | 93,593 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-05-21 | D | 17,926 | 6 | 112,351 | Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-05-21 | D | 2,157 | 6 | 13,519 | Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-05-21 | D | 1,418 | 6 | 8,887 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-05-21 | D | 7,861 | 6 | 49,269 | Common | Form 4 ↗ |
| Eric Duane Foster | Chief Commercial Officer | 2026-05-21 | D | 2,427 | 6 | 15,211 | Common | Form 4 ↗ |
| Susan Hohenleitner | Chief Financial Officer | 2026-05-21 | D | 1,455 | 6 | 9,119 | Common | Form 4 ↗ |
| Eric Duane Foster | Chief Commercial Officer | 2026-05-21 | D | 2,405 | 6 | 15,073 | Common | Form 4 ↗ |
| Mike Kelliher | Chief Business Officer | 2026-05-21 | D | 2,900 | 6 | 18,176 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-05-21 | D | 14,028 | 6 | 87,920 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-06-15 | D | 20,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Raab | Director | 2026-06-15 | A | 20,833 | 1 | 20,625 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-06-15 | D | 41,666 | 6 | 236,346 | Common, open-market sale | Form 4 ↗ |
| William Bertrand, Jr | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Rodgers | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| Richard Rodgers | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Onaiza Cadoret-Manier | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| Onaiza Cadoret-Manier | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Muna Bhanji | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| William Bertrand, Jr | Director | 2026-06-16 | A | 12,345 | 0 | 0 | Common | Form 4 ↗ |
| William Bertrand, Jr | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| Robert Bazemore | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| Merdad Parsey | Director | 2026-06-16 | A | 26,455 | 0 | 0 | Common | Form 4 ↗ |
| David Mott | Director | 2026-06-16 | A | 20,282 | 0 | 0 | Common, indirect | Form 4 ↗ |
| David Mott | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Muna Bhanji | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Bazemore | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Merdad Parsey | Director | 2026-06-16 | A | 39,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-06-18 | D | 31,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-06-18 | D | 81,898 | 6 | 490,487 | Common, open-market sale | Form 4 ↗ |
| Laura A. Williams | Chief Patient Officer | 2026-06-18 | A | 31,000 | 1 | 30,690 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-07-15 | D | 41,668 | 5 | 210,923 | Common, open-market sale | Form 4 ↗ |
| Michael Raab | Director | 2026-07-15 | A | 20,834 | 1 | 20,626 | Common | Form 4 ↗ |
| Michael Raab | Director | 2026-07-15 | D | 20,834 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Susan Hohenleitner | RSU | 2025-10-13 | — | — | 146,896 | — | $735,949 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 343,687 | — | 319,629 |
| Elizabeth Grammer | RSU | 2025-02-25 | — | — | 136,680 | — | 708,002 |
| Susan Hohenleitner | OPTION | 2025-10-13 | — | — | 578,104 | — | 2,194,078 |
| Michael Raab | RSU | 2025-02-25 | — | — | 570,217 | — | 2,953,724 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 119,583 | — | 74,141 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 93,967 | — | 103,364 |
| Edward Conner | OPTION | 2025-08-08 | — | — | 463,268 | — | 1,836,116 |
| Elizabeth Grammer | OPTION | 2025-02-25 | — | — | 205,019 | — | 818,025 |
| John Bishop | RSU | 2025-07-14 | — | — | 218,000 | — | 1,004,980 |
| Michael Raab | OPTION | 2025-02-25 | — | — | 855,326 | — | 3,413,948 |
| Justin Renz | RSU | 2025-02-25 | — | — | 136,680 | — | 708,002 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 195,017 | — | 126,761 |
| Justin Renz | OPTION | 2025-02-25 | — | — | 205,019 | — | 818,313 |
| John Bishop | OPTION | 2025-07-14 | — | — | 327,000 | — | 1,148,032 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 121,000 | — | 35,090 |
| Justin Renz | OPTION | 2025-11-13 | — | — | 146,755 | — | 101,261 |
| Edward Conner | RSU | 2025-08-08 | — | — | 302,260 | — | 1,574,775 |
| Justin Renz | RSU | 2025-11-13 | — | — | 109,635 | — | 474,720 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Susan Hohenleitner | $735,949 | $0 | $2,194,078 | 0.0% |
| Justin Renz | 1,182,722 | 0 | 1,578,559 | 0.0% |
| Elizabeth Grammer | 708,002 | 0 | 818,025 | 0.0% |
| Michael Raab | 2,953,724 | 0 | 3,413,948 | 0.0% |
| Edward Conner | 1,574,775 | 0 | 1,836,116 | 0.0% |
| John Bishop | 1,004,980 | 0 | 1,148,032 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Raab | RSU | 62,500 | — | $364,375 |
| Susan Hohenleitner | Option | 578,104 | 5.01 | — |
| Michael Raab | RSU | 463,300 | — | 2,701,039 |
| Michael Raab | RSU | 237,496 | — | 1,384,602 |
| Susan Hohenleitner | RSU | 146,896 | — | 856,404 |
| Elizabeth Grammer | RSU | 111,051 | — | 647,427 |
| Elizabeth Grammer | RSU | 63,872 | — | 372,374 |
| Elizabeth Grammer | Option | 95,063 | 2.75 | — |
| Michael Raab | RSU | 37,500 | — | 190,125 |
| John Bishop | Option | 327,000 | 4.61 | — |
| Michael Raab | Option | 315,575 | 8.78 | — |
| Michael Raab | Option | 304,417 | 2.75 | — |
| Elizabeth Grammer | Option | 4,084 | 0.99 | — |
| Michael Raab | Option | 677,134 | 5.18 | — |
| Elizabeth Grammer | Option | 162,307 | 5.18 | — |
| Elizabeth Grammer | Option | 85,417 | 8.78 | — |
| John Bishop | RSU | 218,000 | — | 1,270,940 |
| Elizabeth Grammer | RSU | 19,500 | — | 113,685 |
| Michael Raab | Option | 14,584 | 0.99 | — |
Our compensation program is designed to support our overarching mission as a company: to develop and commercialize innovative medicines that address unmet patient needs.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 137,617,786 | 9,413,395 | 759,621 | 93.6% | Passed |
| 2025 | 2025-06-18 | 131,263,613 | 11,095,853 | 693,435 | 92.21% | Passed |
| 2024 | 2024-06-14 | 116,195,368 | 7,710,125 | 1,058,008 | 93.78% | Passed |
| 2023 | 2023-06-15 | 91,624,106 | 14,569,831 | 1,612,753 | 86.28% | Passed |
| 2021 | 2021-06-16 | 69,356,278 | 2,313,136 | 42,867 | 96.71% | Passed |
| 2020 | 2020-06-09 | 66,880,304 | 655,273 | 85,167 | 99.03% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-16 | 93.6%a |
| 2025 | 2025-06-18 | 92.21%b |
| 2024 | 2024-06-14 | 93.78%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast for the foregoing purpose, and will have no effect on the vote for this proposal.”.
b. Approved under the standard stated in the filing — “2), you may vote " FOR ," " AGAINST " or " ABSTAIN ." Abstentions and broker non-votes will have no effect on the vote for this proposal.”.
c. Approved under the standard stated in the filing — “With respect to the approval of the Amended and Restated 2014 Employee Stock Purchase Plan (Proposal 3), you may vote " FOR ," " AGAINST " or " ABSTAIN ." Abstentions and broker non-votes will have no effect on the vote for this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 25 : 1 |
|---|---|
| CEO total compensation | $7,796,171 |
| Median employee compensation | $311,004 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Merdad ParseyIndependent · Nominating and Corporate Governance · Newly elected | $55,000 | $225,000 | $223,349 | $0 | $0 | $503,349 |
| David MottIndependent · Board Chair · Audit and Compliance · Compensation and Leadership Development (Chair) | 112,500 | 149,999 | 149,387 | 0 | 0 | 411,886 |
| Richard RodgersIndependent · Audit and Compliance (Chair) · Compensation and Leadership Development | 77,500 | 149,999 | 149,387 | 0 | 0 | 376,886 |
| William Bertrand, JrIndependent · Audit and Compliance · Nominating and Corporate Governance (Chair) | 70,000 | 149,999 | 149,387 | 0 | 0 | 369,386 |
| Robert BazemoreIndependent · Compensation and Leadership Development | 57,500 | 149,999 | 149,387 | 0 | 0 | 356,886 |
| Muna BhanjiIndependent · Compensation and Leadership Development | 57,500 | 149,999 | 149,387 | 0 | 0 | 356,886 |
| Onaiza Cadoret-ManierIndependent · Nominating and Corporate Governance | 55,000 | 149,999 | 149,387 | 0 | 0 | 354,386 |
| Michael RaabEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $299,386 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $485,000 |
| Equity awards (grant-date value) | $1,124,994 |
| All other compensation | $0 |
| Total cost of the board | $1,609,994 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Ardelyx, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Ardelyx, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutix, Inc. | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | TG Therapeutics, Inc. | 2025 | Michael Weiss | 875,000 | 23,550,000 | 0 | 1,146,250 | 25,571,250 |
| 3 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 4 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 5 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 6 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 7 | ADMA Biologics, Inc. | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 8 | MannKind Corporation | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 9 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 11 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 12 | Ardelyx, Inc. | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 13 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 14 | Arcutis Biotherapeutics, Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 15 | Tarsus Pharmaceuticals, Inc. | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 16 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 17 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 18 | Innoviva, Inc. | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 19 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 20 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Ardelyx, Inc. | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| ADMA Biologics, Inc. | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Amicus Therapeutics, Inc. | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Arcutis Biotherapeutics, Inc. | 125% | not disclosed | No | Pay Governance |
| BioCryst Pharmaceuticals, Inc. | 170% | not disclosed | not disclosed | Aon Human Capital Solutions (division of Aon plc) |
| Catalyst Pharmaceuticals, Inc. | 105% | not disclosed | not disclosed | Mercer LLC (a business of Marsh McLennan) |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Innoviva, Inc. | 105% | not disclosed | not disclosed | Meridian |
| Ironwood Pharmaceuticals, Inc. | 100% | PSU 50 · RSU 50 | Yes — relative total stockholder return (rTSR) | Alpine Rewards LLC |
| MannKind Corporation | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Mirum Pharmaceuticals, Inc. | 200% | not disclosed | No | Alpine Rewards |
| Ocular Therapeutix, Inc. | 145% | not disclosed | No | Aon |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance LLC |
| Tarsus Pharmaceuticals, Inc. | 108% | Options 50 · RSU 50 | No | Pay Governance |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Raab | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 2 | Section 01, Edward Conner | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 3,623,910. Filing ↗machine: r7 · c25 · span 701198–701207 |
| 3 | Section 01, Justin Renz | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 3,551,684. Filing ↗machine: r11 · c25 · span 721168–721177 |
| 4 | Section 01, Susan Hohenleitner | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 3,437,372. Filing ↗machine: r5 · c25 · span 690962–690971 |
| 5 | Section 01, John Bishop | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 2,512,522. Filing ↗machine: r6 · c25 · span 696508–696517 |
| 6 | Section 01, Elizabeth Grammer | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “2025 Summary Compensation Table”. As printed: 2,303,617. Filing ↗machine: r8 · c25 · span 706980–706989 |
| 7 | Section 03, Susan Hohenleitner RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r7 · c25 · span 778857–778864 |
| 8 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r23 · c25 · span 856507–856514 |
| 9 | Section 03, Elizabeth Grammer RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r16 · c25 · span 824015–824022 |
| 10 | Section 03, Susan Hohenleitner OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r6 · c28 · span 774367–774376 |
| 11 | Section 03, Michael Raab RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r4 · c25 · span 764424–764433 |
| 12 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r24 · c25 · span 861042–861048 |
| 13 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r25 · c25 · span 865572–865579 |
| 14 | Section 03, Edward Conner OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r12 · c28 · span 804165–804174 |
| 15 | Section 03, Elizabeth Grammer OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r15 · c28 · span 818753–818760 |
| 16 | Section 03, John Bishop RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r10 · c25 · span 794135–794144 |
| 17 | Section 03, Michael Raab OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r3 · c28 · span 759200–759209 |
| 18 | Section 03, Justin Renz RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r19 · c25 · span 838539–838546 |
| 19 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r20 · c25 · span 843031–843038 |
| 20 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r18 · c28 · span 834006–834013 |
| 21 | Section 03, John Bishop OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r9 · c28 · span 788911–788920 |
| 22 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r22 · c25 · span 852016–852022 |
| 23 | Section 03, Justin Renz OPTION | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r21 · c25 · span 847523–847530 |
| 24 | Section 03, Edward Conner RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r13 · c25 · span 808665–808674 |
| 25 | Section 03, Justin Renz RSU | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r26 · c25 · span 870104–870111 |
| 26 | Section 07, pay ratio | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “CEO Pay Ratio”. As printed: 25 : 1. Filing ↗machine: span 1205748–1205750 |
| 27 | Section 08, Merdad Parsey | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 503,349. Filing ↗machine: t63 · r8 · c13 · span 316383–316390 |
| 28 | Section 08, David Mott | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 411,886. Filing ↗machine: t63 · r6 · c13 · span 311260–311267 |
| 29 | Section 08, Richard Rodgers | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 376,886. Filing ↗machine: t63 · r7 · c13 · span 313697–313704 |
| 30 | Section 08, William Bertrand, Jr | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 369,386. Filing ↗machine: t63 · r3 · c13 · span 303299–303306 |
| 31 | Section 08, Robert Bazemore | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 356,886. Filing ↗machine: t63 · r2 · c13 · span 300856–300863 |
| 32 | Section 08, Muna Bhanji | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 356,886. Filing ↗machine: t63 · r4 · c13 · span 306068–306075 |
| 33 | Section 08, Onaiza Cadoret-Manier | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 354,386. Filing ↗machine: t63 · r5 · c13 · span 308490–308497 |
| 34 | Section 08, Michael Raab | DEF 14A | 2026-04-29 | 0001140361-26-017800 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 02, Michael Raab 2026-05-15 | Form 4 | 2026-05-19 | 0001321402-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Michael Raab 2026-05-15 | Form 4 | 2026-05-19 | 0001321402-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Michael Raab 2026-05-15 | Form 4 | 2026-05-19 | 0001321402-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Joseph James Reilly 2026-05-21 | Form 4 | 2026-05-22 | 0002044416-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Joseph James Reilly 2026-05-21 | Form 4 | 2026-05-22 | 0002044416-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, John Bishop 2026-05-21 | Form 4 | 2026-05-22 | 0001308911-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, James Parker Brady 2026-05-21 | Form 4 | 2026-05-22 | 0002088887-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Eric Duane Foster 2026-05-21 | Form 4 | 2026-05-22 | 0002034148-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Mike Kelliher 2026-05-21 | Form 4 | 2026-05-22 | 0001987188-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Mike Kelliher 2026-05-21 | Form 4 | 2026-05-22 | 0001987188-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Laura A. Williams 2026-05-21 | Form 4 | 2026-05-22 | 0001869194-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Laura A. Williams 2026-05-21 | Form 4 | 2026-05-22 | 0001869194-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Michael Raab 2026-05-21 | Form 4 | 2026-05-22 | 0001321402-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Michael Raab 2026-05-21 | Form 4 | 2026-05-22 | 0001321402-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Laura A. Williams 2026-05-21 | Form 4 | 2026-05-22 | 0001869194-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Laura A. Williams 2026-05-21 | Form 4 | 2026-05-22 | 0001869194-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Michael Raab 2026-05-21 | Form 4 | 2026-05-22 | 0001321402-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Eric Duane Foster 2026-05-21 | Form 4 | 2026-05-22 | 0002034148-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Susan Hohenleitner 2026-05-21 | Form 4 | 2026-05-22 | 0002093095-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Eric Duane Foster 2026-05-21 | Form 4 | 2026-05-22 | 0002034148-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Mike Kelliher 2026-05-21 | Form 4 | 2026-05-22 | 0001987188-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Michael Raab 2026-05-21 | Form 4 | 2026-05-22 | 0001321402-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael Raab 2026-06-15 | Form 4 | 2026-06-17 | 0001321402-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Michael Raab 2026-06-15 | Form 4 | 2026-06-17 | 0001321402-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Michael Raab 2026-06-15 | Form 4 | 2026-06-17 | 0001321402-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, William Bertrand, Jr 2026-06-16 | Form 4 | 2026-06-18 | 0001291937-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Richard Rodgers 2026-06-16 | Form 4 | 2026-06-18 | 0001313397-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Richard Rodgers 2026-06-16 | Form 4 | 2026-06-18 | 0001313397-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, David Mott 2026-06-16 | Form 4 | 2026-06-18 | 0001219871-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Onaiza Cadoret-Manier 2026-06-16 | Form 4 | 2026-06-18 | 0001799355-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Onaiza Cadoret-Manier 2026-06-16 | Form 4 | 2026-06-18 | 0001799355-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Muna Bhanji 2026-06-16 | Form 4 | 2026-06-18 | 0001846905-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, William Bertrand, Jr 2026-06-16 | Form 4 | 2026-06-18 | 0001291937-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, William Bertrand, Jr 2026-06-16 | Form 4 | 2026-06-18 | 0001291937-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Robert Bazemore 2026-06-16 | Form 4 | 2026-06-18 | 0001620152-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Merdad Parsey 2026-06-16 | Form 4 | 2026-06-18 | 0001792150-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, David Mott 2026-06-16 | Form 4 | 2026-06-18 | 0001219871-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, David Mott 2026-06-16 | Form 4 | 2026-06-18 | 0001219871-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Muna Bhanji 2026-06-16 | Form 4 | 2026-06-18 | 0001846905-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Robert Bazemore 2026-06-16 | Form 4 | 2026-06-18 | 0001620152-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Merdad Parsey 2026-06-16 | Form 4 | 2026-06-18 | 0001792150-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Laura A. Williams 2026-06-18 | Form 4 | 2026-06-22 | 0001869194-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Laura A. Williams 2026-06-18 | Form 4 | 2026-06-22 | 0001869194-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Laura A. Williams 2026-06-18 | Form 4 | 2026-06-22 | 0001869194-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Michael Raab 2026-07-15 | Form 4 | 2026-07-17 | 0001321402-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Michael Raab 2026-07-15 | Form 4 | 2026-07-17 | 0001321402-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Michael Raab 2026-07-15 | Form 4 | 2026-07-17 | 0001321402-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 06, 2026 vote | Form 8-K | 2026-06-17 | 0001437402-26-000029 | Item 5.07 · say-on-pay result. As reported: 93.6% (votes for as printed: 137,617,786). Filing ↗ |
| 83 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0001628280-25-032172 | Item 5.07 · say-on-pay result. As reported: 92.21% (votes for as printed: 131,263,613). Filing ↗ |
| 84 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0001628280-24-028413 | Item 5.07 · say-on-pay result. As reported: 93.78% (votes for as printed: 116,195,368). Filing ↗ |
| 85 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 86 | Section 09b board cost (computed) | Computed | — | computed | Cash 485,000 + equity 1,124,994 + all other 0 = 1,609,994, summed across the director compensation table rows.machine: formula: Σ = 1,609,994 |
| 87 | Ocular Therapeutix, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053176 | CEO total compensation as printed in Ocular Therapeutix, Inc.'s own proxy. As printed: 35,946,958. Filing ↗machine: t128 · r3 · c15 · span 574379–574389 |
| 88 | TG Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014233 | CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561 |
| 89 | Rhythm Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 90 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 91 | Vericel Corporation, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 92 | Mirum Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 93 | ADMA Biologics, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001140361-26-014799 | CEO total compensation as printed in ADMA Biologics, Inc.'s own proxy. As printed: 10,237,326. Filing ↗machine: r2 · c25 · span 619659–619670 |
| 94 | MannKind Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145613 | CEO total compensation as printed in MannKind Corporation's own proxy. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621 |
| 95 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 96 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 97 | Dynavax Technologies Corporation, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗ |
| 98 | Ardelyx, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx, Inc.'s own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 99 | Catalyst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗machine: r3 · c31 · span 285833–285842 |
| 100 | Arcutis Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001787306-26-000028 | CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824 |
| 101 | Tarsus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001819790-26-000028 | CEO total compensation as printed in Tarsus Pharmaceuticals, Inc.'s own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 102 | Evolus, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001570562-26-000059 | CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. Filing ↗machine: span 499358–499367 |
| 103 | Xencor, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 104 | Innoviva, Inc., Section 10b CEO total | DEF 14A | 2026-03-24 | 0001140361-26-010912 | CEO total compensation as printed in Innoviva, Inc.'s own proxy. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487 |
| 105 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191 |
| 106 | Collegium Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 107 | Section 10a, Ocular Therapeutix, Inc. reciprocity | DEF 14A | — | 0001104659-26-053176 | Ocular Therapeutix, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 108 | Section 10a, Dynavax Technologies Corporation reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies Corporation's most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 109 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 110 | Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 111 | Section 10a, Collegium Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 112 | Section 10a, MannKind Corporation reciprocity | DEF 14A | — | 0001193125-26-145613 | MannKind Corporation's most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 113 | Section 10a, Mirum Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 114 | Section 10a, Tarsus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001819790-26-000028 | Tarsus Pharmaceuticals, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 115 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 116 | Section 10a, Evolus, Inc. reciprocity | DEF 14A | — | 0001570562-26-000059 | Evolus, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 117 | Section 10a, TG Therapeutics, Inc. reciprocity | DEF 14A | — | 0001437749-26-014233 | TG Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 118 | Section 10a, Xencor, Inc. reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 119 | Section 10a, Rhythm Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 120 | Section 10a, Vericel Corporation reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel Corporation's most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 121 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 122 | Section 10a, Innoviva, Inc. reciprocity | DEF 14A | — | 0001140361-26-010912 | Innoviva, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |
| 123 | Section 10a, Arcutis Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001787306-26-000028 | Arcutis Biotherapeutics, Inc. names Ardelyx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 124 | Section 10a, ADMA Biologics, Inc. reciprocity | DEF 14A | — | 0001140361-26-014799 | ADMA Biologics, Inc.'s most recent proxy was read; its disclosed peer group does not include Ardelyx, Inc.. Filing ↗ |